Finer Wealth Management’s AbbVie ABBV Stock Holding History

Finer Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$607K	Buy	2,410 +92	+4%	+$19.8K	0.27%	54
2026 Q1	$504K	Buy	2,318 +9	+0.4%	+$2K	0.25%	57
2025 Q4	$528K	Buy	2,309 +1,287	+126%	+$293K	0.26%	55
2025 Q3	$237K	Buy	+1,022	New	+$208K	0.12%	79
2025 Q2	–	Sell	-1,022	Closed	-$214K	–	87
2025 Q1	$214K	Buy	+1,022	New	+$199K	0.13%	79
2024 Q4	–	Sell	-1,025	Closed	-$202K	–	83
2024 Q3	$202K	Buy	+1,025	New	+$191K	0.12%	75

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Finer Wealth Management's ABBV Position: Q2 2026 in Review

Finer Wealth Management increased its AbbVie (ABBV) stake by 4% in Q2 2026, buying an estimated $19.8K and bringing the position to 2,410 shares worth $607K. The position accounts for 0.27% of the portfolio, ranked #54.

Finer Wealth Management first reported a position in ABBV in Q3 2024 and has held it in 6 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Finer Wealth Management held 2,410 shares of AbbVie worth $607K as of Q2 2026.
Finer Wealth Management bought 92 AbbVie shares in Q2 2026, an estimated $19.8K.
AbbVie made up 0.27% of Finer Wealth Management's portfolio in Q2 2026, its #54 holding.
Finer Wealth Management first reported a position in AbbVie in Q3 2024 and has held it in 6 quarters since.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Finer Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.